This printed article is located at https://acrometa.listedcompany.com/news.html

News

BackJan 30, 2023
Announcement Title Change - Announcement of Appointment
Date & Time of Broadcast Jan 30, 2023 23:36
Status New
Announcement Sub Title APPOINTMENT OF AN EXECUTIVE DIRECTOR
Announcement Reference SG230130OTHR6F6W
Submitted By (Co./ Ind. Name) Lim Say Chin
Designation Executive Chairman and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below) Appointment of Mr Levin Lee Keng Weng as an Executive Director of the Company with effect from 30 January 2023.

This announcement has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Chua Hiang Hwee Jerry, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com
Additional Details
Date Of Appointment 30/01/2023
Name Of Person Levin Lee Keng Weng
Age 55
Country Of Principal Residence Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process) The Nominating Committee ("NC") had reviewed the qualifications and working experience of Mr Levin Lee Keng Weng ("Mr Lee") and recommended his appointment. The Board of Directors, having considered the NC's recommendation, approved the appointment of Mr Lee as an Executive Director of the Company.
Whether appointment is executive, and if so, the area of responsibility Executive
1. Corporate Finance - to seek investors, raise funds for the Company either through new equity raisings, bank loans, warrants, rights or options to support the Company's current and future objectives;
2. Business Development - to explore and assess new business for future expansion of the Company; and
3. Investor Relations - to manage investor relations and shareholder communication.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.) Chairman
Professional qualifications Nil
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries Nil
Conflict of interests (including any competing business) Nil
Working experience and occupation(s) during the past 10 years Ace Peak Capital Group Private Limited - Director
Sino Pacific Capital Limited - Fund Manager
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6)) Yes
Shareholding interest in the listed issuer and its subsidiaries? Yes
Shareholding Details Direct interest - 55,000,000 shares
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years) Wincash Apolo Gold & Energy Inc.
Grand Ages Precious Metals Ltd
Nutryfarm International Limited
Present Ace Peak Capital Group Private Limited
Sino Pacific Capital Limited
Jubilee Industries Holdings Limited
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner? No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency? No
(c) Whether there is any unsatisfied judgment against him? No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose? No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach? No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part? No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust? No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust? No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity? No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust? No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere? Yes
If Yes, Please provide full details On 4 November 2022, SGX sent a notice to Mr Lee and others (all directors of Nutryfarm International Limited as at 10 January 2022) asserting they had breached Listing Rule 703(1)(b) for failing to disclose material information promptly. On 23 December 2022, Mr Lee filed his Defence explaining that he did not commit any breach. There has been no reply or sanction from SGX so far.
Any prior experience as a director of an issuer listed on the Exchange? Yes
If Yes, Please provide details of prior experience Mr Lee was an Executive Director of Nutryfarm International Limited and is currently an Independent Director of Jubilee Industries Holdings Limited
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable) N.A.
Copyright © 2024 ACROMEC. All Rights Reserved.